- Conditions
- Colorectal Cancer, Depression, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Fatigue, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Lung Cancer, Pancreatic Cancer
- Interventions
- escitalopram oxalate, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 1,089
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Primary Stage IV Hepatobiliary, Esophageal, Colorectal Cancer, Glioblastoma, Cancer of Stomach, Cancer of Pancreas, Melanoma, Head or Neck Cancer, Stage III, Stage IV, Lung Cancers, Pancreatic Cancers
- Interventions
- GoC intervention
- Behavioral
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • New York, New York
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Tucson, Arizona • Kenner, Louisiana • Baltimore, Maryland + 2 more
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan, Nivolumab, Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection, Questionnaire Administration
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 791
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 508 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
- Interventions
- FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 508
- States / cities
- Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
- Conditions
- Progressive Metastatic Malignancies
- Interventions
- ALT-801
- Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more
- Conditions
- Solid Tumor
- Interventions
- CPO-100
- Drug
- Lead sponsor
- Conjupro Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New Haven, Connecticut • Las Vegas, Nevada + 5 more
- Conditions
- Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
- Interventions
- Tislelizumab, Capecitabine, 5-fluorouracil (5-FU), Oxaliplatin, Leucovorin
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Bullhead City, Arizona • Cerritos, California • Los Angeles, California + 6 more
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma
- Interventions
- Allogeneic natural killer (NK) cell
- Genetic
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more
- Conditions
- Advanced Solid Tumors
- Interventions
- KBP-5209
- Drug
- Lead sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana • Houston, Texas • Salt Lake City, Utah
- Conditions
- Advanced or Metastatic Solid Tumors, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer
- Interventions
- NC410
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Bethesda, Maryland • Hackensack, New Jersey • New York, New York + 2 more
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Interventions
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Westwood, Kansas
- Conditions
- Fundic Gland Polyps
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Clinical Stage 0 Gastric Cancer AJCC v8, Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Pathologic Stage 0 Gastric Cancer AJCC v8, Pathologic Stage I Gastric Cancer AJCC v8, Pathologic Stage IA Gastric Cancer AJCC v8, Pathologic Stage IB Gastric Cancer AJCC v8, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIA Gastric Cancer AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8
- Interventions
- Best Practice, Quality-of-Life Assessment, Questionnaire Administration
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
- Interventions
- Avelumab, Irinotecan, Paclitaxel, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more
- Conditions
- Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
- Interventions
- NS-9 [Poly I: Poly C]
- Drug
- Lead sponsor
- NS Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Houston, Texas
- Conditions
- Gastric Cancer, Esophageal Neoplasms
- Interventions
- T900607-sodium intravenous
- Drug
- Lead sponsor
- Tularik
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 5
- States / cities
- Los Gatos, California • San Diego, California • Tampa, Florida + 2 more
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Diffuse Gastric Adenocarcinoma, Gastric Intestinal Type Adenocarcinoma, Gastric Mixed Adenocarcinoma, Recurrent Gastric Carcinoma
- Interventions
- Akt Inhibitor MK2206
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 186
- States / cities
- Mobile, Alabama • Fairbanks, Alaska • Tucson, Arizona + 124 more
- Conditions
- Marginal Zone Lymphoma
- Interventions
- Rituximab, Ibritumomab Tiuxetan
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Quality of Life, Small Intestine Cancer
- Interventions
- bowel obstruction management, quality-of-life assessment
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Stomach Neoplasms, Metastatic or Locally Advanced Gastric Cancer, Metastatic or Local Advanced GE Junction Cancer
- Interventions
- huC242-DM4
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Stomach Neoplasm
- Interventions
- Blood Collection, processing and analyses, Gastroscopy and biopsies collection, Urea Breath Test
- Procedure · Diagnostic Test
- Lead sponsor
- National University Hospital, Singapore
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 500 participants
- Timeline
- 2019 – 2033
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Bile Duct Carcinoma, Gallbladder Carcinoma, Pancreatic Ductal Adenocarcinoma
- Interventions
- Endoscopic Retrograde Cholangiopancreatography
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
- Interventions
- Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
- Drug
- Lead sponsor
- Ashwin Somasundaram
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more